The trial accomplished both equally its Key endpoints, with semaglutide two.four mg demonstrating statistically significant and superior advancements in liver fibrosis without having worsening of steatohepatitis, along with resolution of steatohepatitis without having worsening of liver fibrosis in those with MASH when compared to placebo.oneThey m